.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 7,683,054

« Back to Dashboard

Details for Patent: 7,683,054

Title:Galenic formulations of organic compounds
Abstract: The present invention relates to a solid oral dosage form comprising a therapeutically effective amount of aliskiren or a pharmaceutically acceptable salt thereof, and wherein the active ingredient is present in an amount of more than 46% by weight based on the total weight of the oral dosage form.
Inventor(s): Rigassi-Dietrich; Petra Gisela (Therwil, CH), Schmid; Martin (Wettingen, CH)
Assignee: Novartis AG (Basel, CH)
Filing Date:Apr 29, 2005
Application Number:11/119,273
Claims:1. A solid oral dosage form comprising aliskiren hemi-fumarate salt present in an amount of about 663 mg per dosage, said dosage form providing a mean maximum plasma concentration of aliskiren of about 420 ng/mL a median of about 2 hours after administration of a single dosage.

2. A solid oral dosage form comprising aliskiren hemi-fumarate salt present in an amount of about 663 mg per dosage, said dosage form providing a mean AUC.sub.0-96 of aliskiren of about 3240 ng h/mL after administration of a single dosage.

3. A solid oral dosage form comprising about 663 mg of aliskiren in the form of a hemi-fumarate salt, and a carrier medium, said dosage form providing a mean maximum plasma concentration of aliskiren within the range of 80% to 120% of about 420 ng/mL a median of about 2 hours after administration of a single dosage, whereby a mean AUC.sub.0-96 of aliskiren is within the range of 80% to 120% of about 3240 ngh/mL.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc